Paratek Pharmaceuticals, Inc. short interest in 2022
In 2022, Paratek Pharmaceuticals, Inc.'s disclosed short interest ran from 7.49% of shares outstanding on 14 Jan 2022 to 6.26% on 30 Dec 2022, a change of -1.23 percentage points. The year's high was 11.33% on 14 Apr 2022 and its low 5.85% on 31 Oct 2022, averaging 8.16% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.72 days on 28 Feb 2022. Full history: Paratek Pharmaceuticals, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023
2022 in figures
- Start of year
- 7.49% (14 Jan 2022)
- End of year
- 6.26% (30 Dec 2022)
- Change
- -1.23 pp
- High
- 11.33% (14 Apr 2022)
- Low
- 5.85% (31 Oct 2022)
- Average
- 8.16%
- Highest days to cover
- 17.72 (28 Feb 2022)
- SEC filings marked
- 4
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 7.49% | 14.47 | |
| 31 Jan 2022 | 7.83% | 10.43 | |
| 15 Feb 2022 | 8.42% | 11.91 | |
| 28 Feb 2022 | 9.01% | 17.72 | |
| 15 Mar 2022 | 9.71% | 16.75 | 10-K filed |
| 31 Mar 2022 | 10.71% | 10.43 | |
| 14 Apr 2022 | 11.33% | 5.31 | |
| 29 Apr 2022 | 11.15% | 11.09 | |
| 13 May 2022 | 10.77% | 8.95 | 10-Q filed |
| 31 May 2022 | 10.22% | 17.38 | |
| 15 Jun 2022 | 9.49% | 12.78 | |
| 30 Jun 2022 | 7.44% | 2.71 | |
| 15 Jul 2022 | 6.54% | 6.79 | |
| 29 Jul 2022 | 7.65% | 14.68 | |
| 15 Aug 2022 | 7.32% | 8.17 | 10-Q filed |
| 31 Aug 2022 | 7.30% | 16.12 | |
| 15 Sep 2022 | 7.74% | 16.47 | |
| 30 Sep 2022 | 8.24% | 10.34 | |
| 14 Oct 2022 | 6.64% | 7.50 | |
| 31 Oct 2022 | 5.85% | 10.40 | |
| 15 Nov 2022 | 5.99% | 7.06 | 10-Q filed |
| 30 Nov 2022 | 6.42% | 9.76 | |
| 15 Dec 2022 | 6.27% | 14.12 | |
| 30 Dec 2022 | 6.26% | 6.03 |
See also: Paratek Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.